In July 2020, the German Medical Journal published an article that caught my attention (Future COVID-19 Vaccination – Citizens are Afraid of Side Effects). According to this, the willingness of citizens in Europe to get
Continue reading
Due to the rising infection rates after the summer break, the uncertainties associated with school reopenings, and in anticipation of an uncertain autumn with further infectious diseases such as influenza, the SARSCoV2 pandemic has once
Continue reading
Since July 15, 2020, a new drug for the treatment of relapsing multiple sclerosis, Zeposia® (active ingredient: Ozanimod), has been available in pharmacies. It should be noted that while the drug is new, it is
Continue readingIn view of a number of inquiries, I assume that a work recently published in the journal Multiple Sclerosis and Related Disorders (MSARD) has caused some confusion. The work deals with the occurrence of COVID-19
Continue readingI make no secret of the fact that I am glad to live in the 21st century and even in a country with excellent hygiene standards. In our society, parasites only play a minor role
Continue reading
It is often emphasized that the Corona crisis also has positive effects – on nature, the climate, the traffic situation. That is certainly true – since we have lived beyond our means at the expense
Continue reading
During the Corona crisis, the focus has shifted to science – never before has societal interest in basic medical science been as high as during the Corona pandemic.
Continue reading
The disadvantage of previous recommendations on MS and COVID 19 is that while these recommendations were made by experts to the best of their knowledge and belief, ultimately there was a lack of data to
Continue readingB lymphocytes are currently of great importance for therapy research in MS. They are a central element in the pathogenesis of MS, on the one hand as important antigen-presenting cells, on the other hand as
Continue reading
Siponimod (Mayzent®) is a newly approved medication for the treatment of active secondary progressive multiple sclerosis. Like Fingolimod (Gilenya®), which is produced by the same manufacturer, Siponimod belongs to the class of so-called S1P receptor
Continue reading
Unsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.
